back to Meetings page
- IMMPACT-XIV Slide Presentations
- 1. What do clinicians want to learn from the results of analgesic RCTs?
- Michael Rowbotham, MD
- 2. Responder analyses, cumulative distribution functions, and other approaches to enhancing clinician understanding
- John Farrar, MD, PhD
- 3. Meta-analyses, NNTs, and the Cochrane Collaboration
- Christopher Eccleston, PhD
- 4. On the interpretation of responder analyses and NNTs
- Stephen Senn, PhD
- 5. General considerations for analgesic risk-benefit analyses
- Nathaniel Katz, MD
- 6. Overview of approaches to risk-benefit assessment
- Louis Garrison, PhD
- 7. Lessons about risk-benefit assessment from OMERACT
- Jasvinder Singh, MD
- 8. Evaluating safety in analgesic clinical trials, including prospective capture of adverse events
- Vibeke Strand, MD
- 9. Risk communication in product labels
- Catherine Gray, PharmD
- 10. Comments
- David Schoenfeld, PhD
- 11. Comments
- Scott Evans, PhD